ITP IMMUNE-MEDIATED THROMBOCYTOPENIA

Clinical trials for ITP IMMUNE-MEDIATED THROMBOCYTOPENIA explained in plain language.

Never miss a new study

Get alerted when new ITP IMMUNE-MEDIATED THROMBOCYTOPENIA trials appear

Sign up with your email to follow new studies for ITP IMMUNE-MEDIATED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial aims to control dangerous blood clots

Disease control Not yet recruiting

This early-stage trial is testing a new drug called TGD001 for people experiencing acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and related blood clotting disorders. The study will first find a safe dose, then test how well it works when given alon…

Matched conditions: ITP IMMUNE-MEDIATED THROMBOCYTOPENIA

Phase: PHASE1, PHASE2 • Sponsor: TargED Biopharmaceuticals B.V. • Aim: Disease control

Last updated Apr 02, 2026 04:42 UTC

ITP IMMUNE-MEDIATED THROMBOCYTOPENIA

Get alerted when new ITP IMMUNE-MEDIATED THROMBOCYTOPENIA trials appear

New drug trial aims to control dangerous blood clots